Cargando…
Corrigendum to “HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia”
Autores principales: | Vitkevičienė, Aida, Skiauterytė, Giedrė, Žučenka, Andrius, Stoškus, Mindaugas, Gineikienė, Eglė, Borutinskaitė, Veronika, Griškevičius, Laimonas, Navakauskienė, Rūta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487093/ https://www.ncbi.nlm.nih.gov/pubmed/32952555 http://dx.doi.org/10.1155/2020/1834190 |
Ejemplares similares
-
HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2019) -
Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission
por: Borutinskaitė, Veronika, et al.
Publicado: (2022) -
Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2022) -
Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling
por: Valiulienė, Giedrė, et al.
Publicado: (2021) -
Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study
por: Norvilas, Rimvydas, et al.
Publicado: (2021)